I like the potential of the CD16 and CD17 trials. I really like the potential also of LL for treating longhaulers. But the endpoints for the longhaulers trials it seems, will be ambiguous, must be ambiguous, and Dr Patterson was a "must have" partner for the longhauler trials and trial protocol design. Dr Patterson has displayed confidence in his "Covid Longhauler Factor" (I have no idea what he calls it), that he derives from his blood work, as a determination of progress in treating longhaulers. I guess the question is whether or not the FDA might except Patterson's "Factor" as a Primary Endpoint for a longhauler trial. Maybe folks on this forum know more about Dr Patterson's longhauler "Factor".